A QALY is [still] a QALY is [still] a QALY? : Evaluating proportional shortfall as the answer to the problem of equity in healthcare allocations.
BMC Med Ethics
; 25(1): 35, 2024 Mar 23.
Article
en En
| MEDLINE
| ID: mdl-38521941
ABSTRACT
Despite clinical evidence of drug superiority, therapeutic modalities, like combination immunotherapy, are mostly considered cost-ineffective due to their high costs per life year(s) gained. This paper, taking an ethical stand, reevaluates the standard cost-effectiveness analysis with that of the more recent justice-enhanced methods and concludes by pointing out the shortcomings of the current methodologies.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Atención a la Salud
Límite:
Humans
Idioma:
En
Revista:
BMC Med Ethics
Asunto de la revista:
ETICA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Alemania